Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Core Insights - Madrigal Pharmaceuticals has reported a transformational year in 2024, highlighted by the FDA approval of Rezdiffra as the first and only treatment for metabolic dysfunction-associated steatohepatitis (MASH) [2] - The company has successfully enrolled over 11,800 patients on Rezdiffra, indicating strong market demand and execution [2][6] - Madrigal is preparing for European expansion in the second half of 2025, following the anticipated EMA decision on Rezdiffra [2][7] Financial Performance - Preliminary fourth-quarter 2024 net sales for Rezdiffra are estimated to be between $100 million and$103 million, while full-year 2024 sales are projected to be between $177 million and$180 million [6][7] - As of year-end 2024, Madrigal's cash, cash equivalents, restricted cash, and marketable securities total approximately $931 million [6][7] Market Context - MASH is expected to become the leading cause of liver transplants in the U.S., with an estimated 1.5 million diagnosed patients, and Madrigal aims to reach around 315,000 patients with moderate to advanced fibrosis [5][9] - The MAESTRO-NASH OUTCOMES trial could further position Rezdiffra as a key treatment option for patients with compensated cirrhosis, addressing a significant unmet medical need [2][7]